Compare DLR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLR | EW |
|---|---|---|
| Founded | 2004 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.3B | 50.2B |
| IPO Year | N/A | 1999 |
| Metric | DLR | EW |
|---|---|---|
| Price | $182.39 | $84.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 21 |
| Target Price | ★ $194.28 | $96.47 |
| AVG Volume (30 Days) | 1.7M | ★ 4.7M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $10.92 | $13.39 |
| Revenue Next Year | $10.56 | $9.78 |
| P/E Ratio | $49.16 | ★ $46.87 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $129.95 | $65.94 |
| 52 Week High | $184.79 | $87.89 |
| Indicator | DLR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 54.09 |
| Support Level | $168.11 | $81.61 |
| Resistance Level | $184.79 | $87.22 |
| Average True Range (ATR) | 3.94 | 2.16 |
| MACD | -0.23 | 0.25 |
| Stochastic Oscillator | 87.87 | 68.62 |
Digital Realty owns and operates over 300 data centers worldwide. It has nearly 40 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to "cold shells," where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has deemphasized cold shells and now primarily provides higher-level service to tenants that outsource their related IT needs to Digital. The company operates as a real estate investment trust.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.